Ozempic vs Jardiance
A side-by-side look at two diabetes medications advertised on TV. Informational only — not medical advice.
| CA Ozempic | CA Jardiance | |
|---|---|---|
| Generic name | semaglutide | empagliflozin |
| Drug class | GLP-1 Receptor Agonist | SGLT2 Inhibitor |
| Treats | Type 2 diabetes | Type 2 diabetes, heart failure, chronic kidney disease |
| Category | Diabetes | Diabetes |
| Manufacturer | Novo Nordisk | Boehringer Ingelheim/Eli Lilly |
| Year approved | 2017 | 2014 |
| FDA warning | Moderate warnings | No boxed warning |
| Est. TV ad spend | $85M | $55M |
| Common side effects | Nausea, Vomiting, Diarrhea, Abdominal pain | Urinary tract infections, Yeast infections, Increased urination, Low blood pressure |
Jardiance
Frequently asked questions
Is Ozempic or Jardiance better?
Neither is universally "better." Ozempic (semaglutide) and Jardiance (empagliflozin) are both used for diabetes, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Ozempic and Jardiance?
Ozempic is a GLP-1 Receptor Agonist made by Novo Nordisk, while Jardiance is a SGLT2 Inhibitor made by Boehringer Ingelheim/Eli Lilly. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Ozempic has the larger estimated TV advertising budget of the two.